Agios Pharmaceuticals Files 8-K Report
Ticker: AGIO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, sec
TL;DR
Agios filed a routine 8-K, mostly boilerplate and exhibits.
AI Summary
On January 13, 2025, Agios Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Agios Pharmaceuticals is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard current report with no indication of new material risks or events.
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 001-36014 (other) — Commission File Number
- 88 Sidney Street, Cambridge, MA 02139 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as well as a Regulation FD disclosure.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 13, 2025.
What is Agios Pharmaceuticals, Inc.'s Commission File Number?
Agios Pharmaceuticals, Inc.'s Commission File Number is 001-36014.
Where are Agios Pharmaceuticals, Inc.'s principal executive offices located?
Agios Pharmaceuticals, Inc.'s principal executive offices are located at 88 Sidney Street, Cambridge, MA 02139.
What is the SIC code for Agios Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Agios Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2025-01-13 07:01:47
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AGIO Nasdaq Global Select
Filing Documents
- d131665d8k.htm (8-K) — 26KB
- d131665dex991.htm (EX-99.1) — 32KB
- d131665dex992.htm (EX-99.2) — 35KB
- g131665ex99_2s10g1.jpg (GRAPHIC) — 94KB
- g131665ex99_2s11g1.jpg (GRAPHIC) — 114KB
- g131665ex99_2s12g1.jpg (GRAPHIC) — 154KB
- g131665ex99_2s13g1.jpg (GRAPHIC) — 93KB
- g131665ex99_2s14g1.jpg (GRAPHIC) — 76KB
- g131665ex99_2s15g1.jpg (GRAPHIC) — 109KB
- g131665ex99_2s16g1.jpg (GRAPHIC) — 135KB
- g131665ex99_2s17g1.jpg (GRAPHIC) — 55KB
- g131665ex99_2s18g1.jpg (GRAPHIC) — 95KB
- g131665ex99_2s19g1.jpg (GRAPHIC) — 77KB
- g131665ex99_2s1g1.jpg (GRAPHIC) — 61KB
- g131665ex99_2s20g1.jpg (GRAPHIC) — 67KB
- g131665ex99_2s21g1.jpg (GRAPHIC) — 73KB
- g131665ex99_2s22g1.jpg (GRAPHIC) — 86KB
- g131665ex99_2s23g1.jpg (GRAPHIC) — 102KB
- g131665ex99_2s24g1.jpg (GRAPHIC) — 27KB
- g131665ex99_2s25g1.jpg (GRAPHIC) — 45KB
- g131665ex99_2s26g1.jpg (GRAPHIC) — 100KB
- g131665ex99_2s27g1.jpg (GRAPHIC) — 116KB
- g131665ex99_2s28g1.jpg (GRAPHIC) — 106KB
- g131665ex99_2s2g1.jpg (GRAPHIC) — 240KB
- g131665ex99_2s3g1.jpg (GRAPHIC) — 95KB
- g131665ex99_2s4g1.jpg (GRAPHIC) — 91KB
- g131665ex99_2s5g1.jpg (GRAPHIC) — 97KB
- g131665ex99_2s6g1.jpg (GRAPHIC) — 63KB
- g131665ex99_2s7g1.jpg (GRAPHIC) — 102KB
- g131665ex99_2s8g1.jpg (GRAPHIC) — 67KB
- g131665ex99_2s9g1.jpg (GRAPHIC) — 81KB
- g131665g0111032951957.jpg (GRAPHIC) — 3KB
- 0001193125-25-004943.txt ( ) — 3845KB
- agio-20250113.xsd (EX-101.SCH) — 3KB
- agio-20250113_lab.xml (EX-101.LAB) — 17KB
- agio-20250113_pre.xml (EX-101.PRE) — 11KB
- d131665d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued January 13, 2025. 99.2 Presentation at the 43 rd Annual J.P. Morgan Healthcare Conference 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Brian Goff Brian Goff Chief Executive Officer